BioArctic AB (BIOA-B) Fair Value & Analysis
Healthcare · SE · Market cap 28.5B SEK
Fair value as of: Jul 12, 2026
From 22 valuation models · updated 9 days ago
Share price −0.5% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 184.11 – kr 362.25 · fair‑value band kr 208.12 – kr 830.77 · the kr 298.00 price screens above the kr 273.15 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BioArctic AB (BIOA-B) currently trades at kr 298.00, while our model-based Fair Value estimate is kr 273.15, implying the stock looks roughly 8.3% fairly valued today. We read business quality at 74/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, BioArctic AB generated revenue of 1.1B SEK at a net margin of 18.6%. Revenue declined 66.1% year over year. It earns a return on equity of 10.3%. The balance sheet holds a net cash position of 968M SEK. Fundamentals as of Jul 12, 2026
Our scenario range runs from kr 208.12 (bear case) to kr 830.77 (bull case); at kr 298.00, the current price sits within that range. The share trades about 18% below its 52-week high and 72% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside, at -8%, BIOA-B screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other ALS diseases. In addition, it offers Lecanemab for intravenous treatment. Further, it is developing Lecanemab for Subcutaneous treatment, which is in registration stage; lecanemab, which is in phase 3 clinical trials for presymptomatic treatment; Exidavnemab, which is in phase 2 clinical trials; Lecanemab back-up, BAN2803, ND3014, and BAN2802 that are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, PD-BT2238 which are in research stage. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BioArctic AB reported revenue of kr 2.0B in FY2025 versus kr 23.1M in FY2021, a compound +204.9%/yr. Reported net income was kr 1.0B in FY2025.
Is BIOA-B fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 4,803 MXN | -38% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$29.70 | HK$26.76 | -10% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BioArctic AB (BIOA-B) undervalued?
What is the fair value of BIOA-B?
What is the quality score of BIOA-B?
What is the revenue of BioArctic AB (BIOA-B)?
What is the net profit margin of BIOA-B?
Does BioArctic AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full BioArctic AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.